DRUG
Nifedipine
* Oral Treatment with Nifedipine capsules (10mg) * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg). * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours. * Maximum Duration of the treatment: 48 hours.
Status
Withdrawn
Phase
Phase 3
Enrollment
0
Locations
0
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
This is a study for pregnant women who have been diagnosed with Threatened Preterm Labor. The principal aim of this study is to compare the efficacy and safety of Nifedipine treatment versus Atosiban treatment over these patients' newborn babies.
Full detailed description
Preterm labor is defined as the presence of uterine contractions of sufficient frequency and intensity to effect progressive effacement and dilation of the cervix prior to term gestation (between 20 and 37 weeks). It is a major health problem of increased incidence, affecting approximately between 7-10% of pregnant women in developed countries with a high socioeconomic costs and high rates of fetal mortality, although perinatal progress. This study may allow to establish the existence of differences in perinatal outcomes and to define the first choice drug for tocolysis.
Interventions
Treatment arms and agents.
DRUG
Atosiban
* Intravenously Treatment with Atosiban (7.5mg/ml) * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours. * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours. * Maximum Duration of the treatment: 48 hours.
Timeline
From registration to results.
First posted
Mar 15, 2011
Study start
Jul 2011
Primary completion
Jul 2012
Study completion
Jul 2013
Results posted
Not reported
Registry updated
Jul 29, 2014
Outcomes
What the study measures.
Primary outcomes
Neonatal Respiratory Distress Syndrome (RDS) at birth
Time frame · Measured in the newborn at birth and at 30 days after labor
* Clinical assessment: results of the Silverman test. Existence of tachypnea, chest wall retractions, auricular flutter, expiratory grunting and chest-abdominal asynchrony. * Need of 02 at birth (maximum Fi02 in the first 24 hours to estimate the immediate distress). Measurement of pCO2 at birth. * Need of mechanic ventilation: invasive/not invasive and duration of it. * Radiologic estimation of the level of hyaline membrane disease * Need of a surfactant and number of used dosages.
Secondary outcomes
Prolongation of the pregnancy in women with Threatened Preterm Labor
Time frame · more than 48 hours/7 days
It will be evaluated as a delay in the labor: hours after starting the treatment: more than 48 hours/more than 7 days of prolongation.
Obstetric results
Time frame · at labor and 24 hours after delivery
Number of days and type of labor.
Presence of the neonatal intracranial hemorrhage
Time frame · First assessment: in the first week.
Determination of the appearance and periventricular hemorrhage degree (I-IV) by transfontelar ultrasound scans.
Presence of neonatal necrotizing enterocolitis
Time frame · at birth and at 30 days after labor
Monitor the need of canalizing the umbilical vein or artery, the days of parenteral nutrition, days to the start of enteral nutrition, type of enteral nutrition (from the mother, artificial or mixed), start of the elimination of meconium, clinical data from the neonatal necrotizing enterocolitis(abdominal strain, vomiting, blood in the feces, septic appearance) and radiologic/ecographic (dilated bowel loops, intestinal pneumatosis, air in portal, pneumoperitoneum).
Presence of Retinopathy of prematurity (ROP)
Time frame · Between the 4th and 6th week of baby life.
Monitor the iGF1 (Insulin-like growth factor 1) levels on the 3rd week of life as well as an assessing the development of retinopathy.
Presence of ductus
Time frame · At birth and 30 days after labor
Clinical assessment (heart murmur, jumpy pulse, worsening of the clinical basal situation), echocardiography (confirmation of the ductus, Al/Ao relation, ductal size), medical or surgical treatment necessity.
Mother Tolerance Results
Time frame · at labor and 24 hours after delivery
Survey to assess the tolerance to the symptomatology induced by the medicines (flush, tachycardia, digestive upsets).
Eligibility
Who can take part.
- Minimum age
- Not reported
- Maximum age
- Not reported
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: The study population and the inclusion criteria is established by patients between the 24th and 33+6th weeks of pregnancy, fixed by an ecography during the first three-month period, and with a threat of preterm labor (TLP), by the American College of Obstetricians and Gynecologists (ACOG's) criteria: * Four contractions or more with a duration of at least 30 seconds during 30 minutes * Documented cervix changes: * The cervix changes in a nulliparous woman are: both cervix tact with 0 to 4 cm of dilatation and cervical effacement of at least a 50% (vaginal ultrasound alternative with cervix length two standard curvatures under the average for the gestational age) * The cervix changes in a multiparous woman are: 1 to 4 cm of dilatation and cervical effacement of at least a 50% (same ecographic alternative as the nulliparous). * Patient who had signed the informed consent. Exclusion Criteria: Exclusion criteria of the pregnant mother and intrauterine fetal: * Prior treatment with a different tocolytic from the ones in the protocol. * Chorioamnionitis. * Premature rupture of membranes. * Vaginal Bleeding. * Major fetal malformations. * Intrauterine growth retardation (IGR): IGR\<percentile 5. * Cardiopathies (aortic stenosis, congestive heart failure). * Blood Pressure lower than 100/60 mmHg. * High transaminase levels. * Uterine malformations. * Use of magnesium sulphate. * Severe hypertensive disorder, defined as blood pressure equal to or greater than 160/100 mmHg or any figure associated with severe preeclampsia. * Non-reassuring cardiac frequency tracing defined as category II and III of National Institute of Child Health and Human Development (NICHD). * Asthmatic patients treated with betamimetics. * Hypertensive patients treated with vasodilators. * Patient in treatment or treated with another product/s in investigation during the four weeks prior to randomization. * Hypersensitivity to any drug of the study.
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Related trials
More studies on Atosiban.
NCT IDStudyPhase / statusEnrollmentUpdated
Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Infertility
Not applicable
Recruiting
792
2025-12
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
University of Electronic Science and Technology of China · Healthy Adult Male
Early Phase 1
Recruiting
250
2025-09
The Effect of Oral Oxytocin and Atosiban on Social Attention
University of Electronic Science and Technology of China · Healhty
Early Phase 1
Recruiting
250
2025-07
Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB)
Children's Hospital of Chongqing Medical University · Cervical Cerclage · Premature Birth
Not applicable
Completed
334
2025-05
Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Preterm Birth
Phase 4
Completed
760
2024-07
In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
University of Sao Paulo General Hospital · Myelomeningocele · Terbutaline Adverse Reaction
Not applicable
Completed
25
2022-06
The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain
Radboud University Medical Center · Endometriosis
Phase 2
Unknown
10
2022-05
Role of Atosiban in Recurrent Implantation Failure
Al Baraka Fertility Hospital · Recurrent Implantation Failure
Not applicable
Unknown
150
2021-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.